BPC-157: Research, Evidence & Limitations

Overview

BPC-157 is a pentadecapeptide studied mainly in preclinical models. Although the experimental literature is large, human clinical evidence remains limited. This hub organizes what has been studied, what class of evidence supports each claim, and which questions are still open.

This page is not a use guide, a recovery protocol, or a treatment monograph. It also does not treat a certificate of analysis as biological proof. The evidence profile is different from that of a compound with a mature clinical-development program: most of what is published here is animal or cellular.

What BPC-157 is

BPC-157 is commonly expanded as Body Protection Compound-157. The literature describes it as a synthetic fifteen-amino-acid peptide — a pentadecapeptide — associated with a fragment studied in work that began with gastric juice.^4,1

The full definition, the nomenclature, and what that identity does not authorize are in What Is BPC-157. This hub only situates the compound.

How it is identified

The sequence commonly cited is GEPPPGKPADDAGLV. That one-letter string corresponds to Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a molecular-identity fact, not an efficacy argument.^7,1

Reviews also record other historical designations. Those labels do not make the peptide an approved drug or an established therapeutic class.¹

What kind of evidence exists

The useful question is not “are there papers?” The useful question is what class they are. A 2026 review describes more than three decades of preclinical work and, at the same time, pharmaceutical development that remains rudimentary: no approved formulation, no validated dosing regimen, and no completed Phase II trial.¹

A finding in a rat, an explant, or a culture does not occupy the same place as a controlled clinical trial. The labels on this page mark that difference on purpose.

Research areas

The areas below are laboratory lines of work, not demonstrated human indications. Online they are often presented as if they were already clinical uses. Here they are named only as objects of study.

• Experimental gastrointestinal models, which concentrate much of the early research interest.^5,4
• Tendon and ligament models, including rat Achilles transection and fibroblast work.^6,7,3
• Broader musculoskeletal models, summarized in orthopedic reviews as a research area, not as proof of a human treatment.³
• Angiogenic and vascular signaling, including experimental VEGFR2-related activation.⁸
• Experimental work on the nitric-oxide system in rat gastric mucosa.⁵

Tendon detail is in BPC-157 and tendons. Gastrointestinal detail is in gastrointestinal models. Proposed mechanisms are in proposed mechanisms in preclinical research.

Available human evidence

The published human evidence we use as an anchor is a 2025 intravenous-infusion pilot in two participants. A study of that size does not establish general safety or clinical efficacy.²

A 2025 orthopedic review, searching through 3 June 2024, found 35 preclinical studies and one clinical study. That count confirms the asymmetry: almost everything is animal work.³

The page that concentrates this point is BPC-157 in humans.

Regulatory status in the United States

BPC-157 is not an FDA-approved drug. On 23 July 2026, the Pharmacy Compounding Advisory Committee discussed BPC-157-related bulk drug substances — free base and acetate — for an ulcerative-colitis nomination under the 503A list. That is not drug approval, not authorization for general human use, and not proof of safety or efficacy.^10,11

Four things should stay separate: FDA staff scientific review, the committee’s advisory recommendation, any later formal rulemaking, and drug approval. They are not the same act. Vote tallies, when mentioned, are cited as trade-press reporting of an advisory recommendation, not as the Agency’s final minutes.^10,13

The detail is in FDA, compounding, and WADA status.

Anti-doping context

On WADA’s 2026 Prohibited List, BPC-157 is named explicitly as an example of a non-approved substance in class S0. Anti-doping status is not a medical decision and not a regulatory approval. Anyone competing under anti-doping rules should verify the current official list.^14,15

What we do not know

• There is no validated human dosing regimen and no approved pharmaceutical formulation.¹
• There is no completed Phase II trial that would support a clinical-efficacy claim.¹
• BPC-157 is not a proven treatment for tendon, muscle, gastrointestinal disease, neurological injury, or any other human disease.
• Mechanisms proposed in cells and rodents do not establish therapeutic action in people.^8,7
• Published pharmacokinetics in rats and dogs do not replace a human pharmacological program.⁹

Explore research

Six supporting pages cover distinct intents: definition, proposed mechanisms, tendon evidence, gastrointestinal evidence, human evidence, and FDA/WADA status. None replaces the others.

Peptra analytical documentation

A certificate of analysis describes lot identity and purity. It does not demonstrate biological efficacy, does not make the material a drug, and does not close the clinical gap described above. See the BPC-157 certificate archive and, if you are looking for the research material, the product page.

To read a COA by method, start with how to read a peptide certificate.